Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by β-carboline and indole derivatives

https://doi.org/10.1016/0003-9861(84)90579-4Get rights and content

Abstract

β-Carboline derivatives inhibited both indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase activities from various sources. Among them, norharman is most potent for both enzymes from mammalian sources. Kinetic studies revealed that norharman is uncompetitive (Ki = 0.12 mm) with l-tryptophan for rabbit intestinal indoleamine 2,3-dioxygenase, and linearly competitive (Ki = 0.29 mm) with l-tryptophan for mouse liver tryptophan 2,3-dioxygenase. In addition, some β-carbolines selectively inhibited one enzyme or the other. Pseudomonad tryptophan 2,3-dioxygenase was inhibited by a different spectrum of β-carbolines. Such a selective inhibition by the structure of substrate analogs is more evident by the use of indole derivatives. Indole-3-acetamide, indole-3-acetonitrile and indole-3-acrylic acid exhibited a potent inhibition for mammalian tryptophan 2,3-dioxygenase, while they moderately inhibited the pseudomonad enzyme. However, they showed no inhibition for indoleamine 2,3-dioxygenase. These results suggest the difference of the structures of the active sites among these enzymes from various sources.

References (23)

  • T. Shimizu et al.

    J. Biol. Chem

    (1978)
  • E. Frieden et al.

    Arch. Biochem. Biophys

    (1961)
  • Y. Watanabe et al.

    Biochem. Biophys. Res. Commun

    (1978)
  • S. Udenfriend et al.

    Biochem. Pharmacol

    (1958)
  • Y. Hashimoto et al.

    Phytochemistry

    (1975)
  • Y. Hashimoto et al.

    Phytochemistry

    (1976)
  • Y. Ishimura
  • G. Ballin

    J. Chromatogr

    (1964)
  • O.H. Lowry et al.

    J. Biol. Chem

    (1951)
  • N.S. Buckholtz et al.

    Biochem. Pharmacol

    (1977)
  • W.E. Müller et al.

    Pharmac. Biochem. Behav

    (1981)
  • Cited by (71)

    • Indoleamine 2,3-dioxygenase

      2023, Metalloenzymes: From Bench to Bedside
    • Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy

      2015, Drug Discovery Today
      Citation Excerpt :

      Given the ‘promiscuous ligand binding site’ of the AhR [64], and evidence indicating AhR ligand-activated signalling leads to increased IDO1 expression [28], the prospect that structurally diverse IDO1, IDO2, and/or TDO inhibitors (e.g., Table 1) might also bind to the AhR, potentially counteracting their immunoregulatory effects, should be further investigated. Norharman (Table 1), for example, is a β-carboline-based inhibitor that has been shown to be effective against IDO1 (Ki 1280 ± 110 μM [16]), IDO2 (mouse Ki 690 ± 50 μM [16]), and TDO (mouse Ki 290 μM [65]). A simple, achiral molecule, norharman is hypothesised to bind directly to the heme centre of IDO1 as a nitrogen-donor ligand that competes with O2 rather than with tryptophan for the enzyme active site.

    • Exploring allosteric activation of LigAB from Sphingobium sp. strain SYK-6 through kinetics, mutagenesis and computational studies

      2015, Archives of Biochemistry and Biophysics
      Citation Excerpt :

      In mammalian cysteine dioxygenase, covalent modification of the enzyme by cysteine (the substrate) produces a non-allosteric activation which then effects an 11 – fold rate enhancement, but is not strictly required for activity [59]. In human indoleamine dioxygenase (IDO), activity (Vmax) is enhanced through binding of synthetic indole derivatives to an auxiliary binding pocket near the active site, leading to a 35–60% rate enhancement (depending upon the pH and effector molecule) [60–64]. Those studies suggested the existence of an auxiliary binding site for IDO allosteric effectors which was recently identified by computational docking studies using the IDO crystal structure [65].

    View all citing articles on Scopus

    This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan, and by grants from the Japanese Foundation on Metabolism and Diseases, Fujiwara Memorial Foundation, the Japan Heart Foundation and Shimadzu Science Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    View full text